Insulet slips 2.5% pre-market on JMP downgrade

Shares of Insulet (PODD) slip 2.5% pre-market after JMP Securities downgrades the insulin device manufacturer to Perform from Outperform, citing increased reports in the FDA's MAUDE database, negative customer feedback online, and higher-than-expected failure rates.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs